Ratings Galapagos NV

Equities

GLPG

BE0003818359

Market Closed - Euronext Amsterdam Other stock markets 11:35:09 2024-05-31 am EDT			5-day change	1st Jan Change
25.74 ^EUR	+1.82%		+1.90%	-30.41%

May. 31	Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	MT
May. 31	Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	MT

Strengths

Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
GALAPAGOS NV	-30.41%	1.84B	B
MODERNA, INC.	+43.36%	54.64B	B-
IQVIA HOLDINGS INC.	-5.31%	39.92B	B
LONZA GROUP AG	+37.52%	38.82B	A
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B	B-
CELLTRION, INC.	-12.56%	26.22B	C
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B	B
BIO-TECHNE CORPORATION	+0.04%	12.16B	B+
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B	B+
MEDPACE HOLDINGS, INC.	+26.04%	11.94B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes